Compare · DFTX vs HAPP
DFTX vs HAPP
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Happiness Development Group Limited (HAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HAPP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 308.9x HAPP ($14.9M).
- DFTX has hit the wire 11 times in the past 4 weeks while HAPP has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for HAPP).
- Company
- Definium Therapeutics Inc.
- Happiness Development Group Limited
- Price
- -
- -
- Market cap
- $4.60B
- $14.9M
- 1M return
- -17.01%
- -
- 1Y return
- +135.57%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 0
- Recent ratings
- 8
- 0
Happiness Development Group Limited
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest HAPP
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form EFFECT filed by Happiness Development Group Limited
- SEC Form F-3 filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form 20-F/A filed by Happiness Development Group Limited (Amendment)
- SEC Form 6-K filed by Happiness Development Group Limited